ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Target Price of $25.00 According to Brokerages

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has earned an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $25.00.

Several research analysts have commented on SPRY shares. Weiss Ratings cut shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Leerink Partners set a $15.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, September 8th.

ARS Pharmaceuticals Stock Performance

NASDAQ:SPRY opened at $4.03 on Monday. The company has a quick ratio of 3.28, a current ratio of 3.48 and a debt-to-equity ratio of 13.72. ARS Pharmaceuticals has a 1-year low of $3.81 and a 1-year high of $13.15. The firm has a market capitalization of $400.78 million, a price-to-earnings ratio of -1.85 and a beta of 0.85. The stock has a fifty day simple moving average of $4.81 and a 200 day simple moving average of $6.82.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.15). The company had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%. Sell-side analysts forecast that ARS Pharmaceuticals will post -1.91 earnings per share for the current year.

Hedge Funds Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. USAdvisors Wealth Management LLC purchased a new stake in shares of ARS Pharmaceuticals in the third quarter valued at $43,000. Bessemer Group Inc. boosted its position in shares of ARS Pharmaceuticals by 3,102.1% in the first quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock worth $61,000 after buying an additional 7,290 shares during the period. Alpine Woods Capital Investors LLC purchased a new position in shares of ARS Pharmaceuticals during the first quarter valued at $80,000. Syon Capital LLC purchased a new position in shares of ARS Pharmaceuticals during the second quarter valued at $80,000. Finally, Allianz Asset Management GmbH purchased a new position in shares of ARS Pharmaceuticals during the second quarter valued at $82,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.